Neoadjuvant Versus Adjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer: A National Cancer Database Study
Background/Objectives: While neoadjuvant chemo-immunotherapy has become a standard treatment for patients with early-stage triple-negative breast cancer (TNBC) based on KEYNOTE-522, the trial did not directly compare neoadjuvant with adjuvant chemo-immunotherapy. We compared treatment patterns and survival outcomes bet...